Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.

Trial Profile

Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Letrozole (Primary) ; Triptorelin (Primary) ; Zoledronic acid (Primary) ; Tamoxifen
  • Indications Early breast cancer; Osteoporosis
  • Focus Therapeutic Use
  • Acronyms HOBOE
  • Most Recent Events

    • 14 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
    • 14 Jul 2017 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018.
    • 27 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top